🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
ENG
$ENGN
🔒 US EquitiesenGene Therapeutics Inc
AVG HISTORICAL GAP
+2.59%
MAX GAP RECORD
+9.73%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $ENGN
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$ENGN
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Sep 08, 2026 Earnings Release 2026-09-08 (BEFORE OPEN) |
+0.00%
|
| Jun 15, 2026 Earnings Release 2026-06-15 (BEFORE OPEN) |
+8.02%
|
| Mar 09, 2026 Earnings Release 2026-03-09 (BEFORE OPEN) |
-7.14%
|
| Dec 22, 2025 Earnings Release 2025-12-22 (AFTER CLOSE) |
+0.00%
|
| Sep 11, 2025 Earnings Release 2025-09-11 (AFTER CLOSE) |
+0.00%
|
| Jun 12, 2025 Earnings Release 2025-06-12 (BEFORE OPEN) |
+4.35%
|
| Mar 10, 2025 Earnings Release 2025-03-10 (AFTER CLOSE) |
+2.10%
|
| Dec 19, 2024 Earnings Release 2024-12-19 (AFTER CLOSE) |
+9.73%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
4.9%
Bullish Gaps (5)
Bearish Gaps (2)
Neutral / Flat (1)
📖 Intelligence Summary
enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗